Developing new drugs to target tau proteins for treating Alzheimer's disease
Official title: Targeting biologically relevant tau monomers and oligomers using a novel DEL drug discovery platform to treat Alzheimer’s disease and tauopathies
Funded at Jillion Therapeutics INC. · NIH-11005644 · Data updated 2026-11-12
This study is looking for new small molecules that can help reduce the harmful effects of tau proteins, which are linked to Alzheimer's disease, to find better treatments for people dealing with this condition.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Jillion Therapeutics INC. NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $496,373 |
| NIH project number | 1R43AG085856-01A1 |
| Project ID | NIH-11005644 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or other tauopathies.
✕Less likely to help
Patients with non-tau related forms of dementia or neurodegenerative diseases may not benefit from this research.
What this research studies
This research focuses on identifying small molecules that can bind to tau proteins, which are implicated in Alzheimer's disease and other tauopathies. Using a novel DNA-encoded library (DEL) drug discovery platform, the project aims to modify the biology of tau proteins to block or reduce their toxicity. The approach addresses the challenges of current tau drug discovery methods, which often require large amounts of non-physiological tau protein and complex systems that are not compatible with high-throughput screening. By targeting tau monomers and oligomers, the research seeks to find effective treatments for neurodegenerative diseases characterized by tau pathology.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for patients suffering from Alzheimer's disease and related conditions.
How similar studies have gone: While targeting tau proteins is a relatively novel approach, there have been promising developments in similar research areas that suggest potential for success.
Where this research is happening
-
Jillion Therapeutics INC.
New York, United States Active
Researchers
- Principal investigator: Flajolet, Marc — Jillion Therapeutics INC.
- Study coordinator: Flajolet, Marc
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.